Background Thymic carcinoma (TC) is a rare, aggressive cancer without a standardized
therapeutic approach in the metastatic context. Recently TCs have been shown to express …

Background: Thymic carcinoma (TC) is a rare cancer with a poor prognosis. Treatment
options are limited, especially after relapse. We previously reported that PD-L1 positivity was …

Introduction Thymic carcinoma (TC) is a rare cancer with a poor prognosis and limited
treatment options, especially after relapse. Methods In this open-label, two-stage …

The remarkable success of immune checkpoint inhibitors (ICIs) against several cancers has
had a significant impact on the management of these diseases and marked the beginning of …

Background Thymic carcinoma (TC) is a rare but highly aggressive cancer, with no standard
treatment for patients who progress after platinum-containing chemotherapy. KN046 is a …

Background: Thymic carcinoma is a rare malignancy, and platinum-based chemotherapy
has not previously been established as a standard treatment for advanced or metastatic …

Thymic carcinoma (TC) is a rare malignant tumor with a poor prognosis, and there is
currently limited data on the use of immunotherapy in patients with unresectable TC. In this …

Background Treatment options are limited for patients with thymic carcinoma. These
aggressive tumours are not typically associated with paraneoplastic autoimmune disorders …

Thymic carcinoma is a relatively rare and aggressive thymic epithelial tumor. Herein, we
report successful treatment of thymic carcinoma with pembrolizumab. A 68-year-old woman …

Background Two phase II studies of pembrolizumab 200 mg every 3 weeks in advanced
thymic carcinoma have recently been published (Giaccone et al. Lancet Oncol. 2018, study# …